Key result
Cellular senescence may drive cardiac lymphatic dysfunction, amplifying edema, inflammation, and fibrosis in HFpEF.
Why the study?
Heart failure with preserved ejection fraction represents the dominant and most therapeutically recalcitrant heart failure phenotype, but its pathophysiology remains incompletely delineated.
This review introduces a novel conceptual framework linking cellular senescence and cardiac lymphatic dysfunction to the pathophysiology of HFpEF, suggesting senolytics as a potential future therapeutic avenue.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for senescence-lymphatic targeting in HFpEF; leaves open causal validation before trials.
Heart failure with preserved ejection fraction (HFpEF) represents the dominant and most therapeutically recalcitrant phenotype of heart failure in the contemporary era, yet its pathophysiology remains incompletely delineated. This narrative review advances a novel mechanistic framework proposing that cellular senescence and, specifically, its principal paracrine effector, the senescence-associated secretory phenotype, orchestrate a progressive impairment of cardiac lymphatic function that critically amplifies the myocardial interstitial edema, chronic inflammation, and fibrotic remodeling that define HFpEF. We critically synthesize emerging evidence from molecular geroscience, lymphatic biology, and cardiac physiology to argue that senescence-associated secretory phenotype-driven lymphatic endothelial dysfunction constitutes a previously underappreciated but mechanistically compelling axis in HFpEF pathobiology. We further discuss the translational implications of this paradigm, including the therapeutic potential of senolytic and senomorphic interventions, the obstacles inherent in cardiac lymphatic imaging and targeted drug delivery, and the ethical considerations surrounding the application of antiaging strategies in a predominantly elderly and comorbid patient population. This synthesis is intended to stimulate interdisciplinary investigation and provide a conceptual scaffold for future clinical trials targeting the senescence-lymphatic interface in HFpEF.
No takes yet. Share an insight, caveat, or question.
A. Moftah (2026) conducted a review in Heart failure with preserved ejection fraction (HFpEF). Cellular senescence and senescence-associated secretory phenotype was evaluated. Cellular senescence and its secretory phenotype may drive cardiac lymphatic dysfunction, amplifying myocardial edema, inflammation, and fibrotic remodeling in heart failure with preserved ejection fraction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: